Gout is a progressive, painful and debilitating inflammatory arthritis. It is caused by elevated serum uric acid (sUA) concentrations, resulting in high uric acid (SUA >6.8 mg/dl). Persistently elevated blood uric acid can lead to deposition of sodium urate (MSU) crystals in joints and soft tissues, which can cause acute and chronic inflammation. The prevalence of hyperuricemia and gout has gradually increased over the last few decades, probably due to an aging population, changes in lifestyle and diet, and an increase in gout-related complications. Untreated or poorly treated gout can lead to chronic symptoms of the disease, including persistent inflammation, an increased number of acute attacks, development of gout stones and structural damage to the joints. There are data suggesting that persistent inflammation and subsequent damage can occur in localized joints and systems, even if the patient is asymptomatic at the time. The goal of long-term treatment of gout is to lower blood uric acid levels <6 mg/dl or less, so that the saturation point of sodium urate is below 6.8 mg/dl, thereby inhibiting the formation of new crystals and promoting the dissolution of existing crystals. Treatment of gout should be aimed at eliminating gout attacks, improving disease prognosis, long-term induction solutions for gout stones, and more effective management of complications, many of which are accompanied by hyperuricemia. Numerous studies have shown that reducing blood uric acid by effective methods, with a treatment goal of <6 mg/dl, can lead to a reduction in acute attacks of gout and to the eventual disappearance of gout stones. Gout is often due to a number of poorly managed factors, including lack of adherence to treatment guidelines by physicians and patients. Patients need to be educated about their diagnosis and disease management, such as the impact of diet and the importance of long-term treatment adherence. Gout is a curable disease if patients adhere to treatment while having their blood uric acid monitored regularly.